Loading...

Sernova

DB:PSH
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PSH
DB
CA$40M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch and associated technologies, including therapeutic cells and local immune protection. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • Sernova has significant price volatility in the past 3 months.
PSH Share Price and Events
7 Day Returns
32.7%
DB:PSH
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-29.6%
DB:PSH
-10.6%
DE Biotechs
-6.2%
DE Market
PSH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sernova (PSH) 32.7% 15% 6.2% -29.6% -17.4% -
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • PSH underperformed the Biotechs industry which returned -10.6% over the past year.
  • PSH underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
PSH
Industry
5yr Volatility vs Market

PSH Value

 Is Sernova undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sernova. This is due to cash flow or dividend data being unavailable. The share price is €0.138.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sernova's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sernova's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PSH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in CAD CA$-0.02
TSXV:SVA Share Price ** TSXV (2019-04-23) in CAD CA$0.23
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sernova.

DB:PSH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:SVA Share Price ÷ EPS (both in CAD)

= 0.23 ÷ -0.02

-9.96x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sernova is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Sernova is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Sernova's expected growth come at a high price?
Raw Data
DB:PSH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.96x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
36%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sernova, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sernova's assets?
Raw Data
DB:PSH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in CAD CA$0.02
TSXV:SVA Share Price * TSXV (2019-04-23) in CAD CA$0.23
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:PSH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:SVA Share Price ÷ Book Value per Share (both in CAD)

= 0.23 ÷ 0.02

13.96x

* Primary Listing of Sernova.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sernova is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Sernova's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sernova has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PSH Future Performance

 How is Sernova expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
36%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sernova expected to grow at an attractive rate?
  • Sernova's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Sernova's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Sernova's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:PSH Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PSH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 36%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PSH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PSH Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-10-31 36 2 1
2022-10-31 0 -2 1
2021-10-31 0 -3 1
2020-10-31 0 -2 1
2019-10-31 0 -4 1
DB:PSH Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-01-31 -4 -4
2018-10-31 -4 -4
2018-07-31 -3 -4
2018-04-30 -3 -3
2018-01-31 -3 -3
2017-10-31 -3 -3
2017-07-31 -3 -2
2017-04-30 -3 -2
2017-01-31 -3 -2
2016-10-31 -3 -2
2016-07-31 -2 -3
2016-04-30 -2 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sernova's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Sernova is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PSH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Sernova Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PSH Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-10-31 0.01 0.01 0.01 1.00
2022-10-31 -0.01 -0.01 -0.01 1.00
2021-10-31 -0.01 -0.01 -0.01 1.00
2020-10-31 -0.01 -0.01 -0.01 1.00
2019-10-31 -0.02 -0.02 -0.02 1.00
DB:PSH Past Financials Data
Date (Data in CAD Millions) EPS *
2019-01-31 -0.02
2018-10-31 -0.02
2018-07-31 -0.02
2018-04-30 -0.02
2018-01-31 -0.02
2017-10-31 -0.02
2017-07-31 -0.01
2017-04-30 -0.01
2017-01-31 -0.01
2016-10-31 -0.02
2016-07-31 -0.02
2016-04-30 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sernova will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sernova's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sernova has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PSH Past Performance

  How has Sernova performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sernova's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sernova does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sernova's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sernova's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Sernova's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sernova Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PSH Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 -3.66 1.48 2.18
2018-10-31 -3.70 1.47 2.23
2018-07-31 -3.84 1.48 2.38
2018-04-30 -3.44 1.29 2.11
2018-01-31 -3.09 1.11 1.98
2017-10-31 -2.64 1.10 1.54
2017-07-31 -1.83 1.05 0.79
2017-04-30 -2.09 1.30 0.88
2017-01-31 -2.14 1.28 0.87
2016-10-31 -2.50 1.30 1.20
2016-07-31 -3.22 1.43 1.77
2016-04-30 -2.92 1.30 1.58
2016-01-31 -2.91 1.23 1.69
2015-10-31 -2.86 1.09 1.79
2015-07-31 -2.65 0.83 1.85
2015-04-30 -2.73 0.62 2.14
2015-01-31 -2.78 0.74 2.09
2014-10-31 -2.75 0.77 2.03
2014-07-31 -2.61 0.76 1.90
2014-04-30 -2.24 0.69 1.61
2014-01-31 -2.07 0.54 1.59
2013-10-31 -2.00 0.49 1.57
2013-07-31 -2.16 0.52 1.69
2013-04-30 -2.35 0.63 1.77
2013-01-31 -2.47 0.68 1.84
2012-10-31 -2.57 0.68 1.92
2012-07-31 -2.34 0.67 1.71
2012-04-30 -2.19 0.57 1.64

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sernova has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sernova has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sernova improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sernova's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sernova has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PSH Health

 How is Sernova's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sernova's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sernova is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sernova has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sernova's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Sernova has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sernova Company Filings, last reported 2 months ago.

DB:PSH Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 2.77 0.00 2.21
2018-10-31 3.26 0.00 2.74
2018-07-31 4.03 0.00 3.80
2018-04-30 2.39 0.00 2.39
2018-01-31 3.20 0.00 3.29
2017-10-31 3.65 0.00 3.63
2017-07-31 4.48 0.00 4.74
2017-04-30 5.12 0.00 5.52
2017-01-31 5.19 0.00 5.51
2016-10-31 5.38 0.00 5.90
2016-07-31 5.37 0.00 6.19
2016-04-30 2.04 0.00 2.90
2016-01-31 2.57 0.00 3.58
2015-10-31 2.95 0.00 2.88
2015-07-31 3.65 0.00 3.51
2015-04-30 2.51 0.00 2.60
2015-01-31 3.18 0.00 3.05
2014-10-31 3.78 0.00 3.42
2014-07-31 4.44 0.00 3.88
2014-04-30 4.95 0.00 4.26
2014-01-31 5.45 0.00 4.63
2013-10-31 6.02 0.00 4.98
2013-07-31 6.54 0.00 5.22
2013-04-30 6.91 0.00 5.37
2013-01-31 7.58 0.00 6.04
2012-10-31 6.07 0.00 4.36
2012-07-31 6.66 0.00 4.76
2012-04-30 6.94 0.00 4.97
  • Sernova has no debt.
  • Sernova has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sernova has less than a year of cash runway based on current free cash flow.
  • Sernova has less than a year of cash runway if free cash flow continues to grow at historical rates of 19.3% each year.
X
Financial health checks
We assess Sernova's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sernova has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PSH Dividends

 What is Sernova's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sernova dividends.
If you bought €2,000 of Sernova shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sernova's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sernova's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PSH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PSH Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2023-10-31
2022-10-31
2021-10-31
2020-10-31
2019-10-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sernova has not reported any payouts.
  • Unable to verify if Sernova's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sernova's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sernova has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sernova's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sernova afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sernova has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PSH Management

 What is the CEO of Sernova's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Philip Toleikis
COMPENSATION CA$647,258
TENURE AS CEO 10 years
CEO Bio

Dr. Philip M. Toleikis, B.A., M.Sc., Ph.D., has been the Chief Executive Officer and the President of Sernova Corp. since April 28, 2009. Dr. Toleikis is a seasoned and Experienced biotechnology executive, with over 20 years of research, intellectual property, management and business experience in the pharmacology and biotechnology sectors. He serves at Clera Inc. He served as the Vice President of R&D Pharmacology and Drug Screening for Angiotech Pharmaceuticals, Inc., where he built a major scientific and information technology team. His major achievements at Angiotech included successful completion of Phase II European Clinical Trials, chairing the Joint Research Committee, in-licensing and out-licensing of technologies and management of key patents and patent applications. Dr. Toleikis's research training and experience art disease, cardiomyopathy, hypertension and aneurysms. Dr. Toleikis has been a Director of Sernova Corp. since June 29, 2009. He is the author of multiple issued patents and over 110 patent applications. Dr. Toleikis completed Post Doctoral work at the BC Cancer Agency and obtained his Ph.D. in Medicine, Pharmacology and Therapeutics from the University of British Columbia He earned an M.Sc. at the University of Michigan and a B.A. at the University of Vermont.

CEO Compensation
  • Philip's compensation has increased whilst company is loss making.
  • Philip's remuneration is higher than average for companies of similar size in Germany.
Management Team

Philip Toleikis

TITLE
President
COMPENSATION
CA$647K
TENURE
10 yrs

Sean Hodgins

TITLE
Chief Financial Officer
TENURE
0.9 yrs

Douglas Maret

TITLE
Chief Science Officer
Board of Directors Tenure

Average tenure and age of the Sernova board of directors in years:

9.8
Average Tenure
53
Average Age
  • The tenure for the Sernova board of directors is about average.
Board of Directors

Frank Holler

TITLE
Chairman
COMPENSATION
CA$43K
AGE
61
TENURE
4.1 yrs

Philip Toleikis

TITLE
President
COMPENSATION
CA$647K
TENURE
9.8 yrs

Jeff Bacha

TITLE
Independent Director
COMPENSATION
CA$36K
AGE
50
TENURE
10.5 yrs

James Parsons

TITLE
Independent Director
COMPENSATION
CA$33K
AGE
53
TENURE
7 yrs

Norman C. Wong

TITLE
Member of Scientific Advisory Board
TENURE
12.8 yrs

Jannette Dufour

TITLE
Member of Scientific Advisory Board
TENURE
12.7 yrs

Clive Patience

TITLE
Member of Scientific Advisory Board
TENURE
12.3 yrs

George King

TITLE
Member of Scientific Advisory Board

Steven Paraskevas

TITLE
Member of Scientific Advisory Board
TENURE
8.3 yrs

Bruce Weber

TITLE
Independent Director
COMPENSATION
CA$32K
TENURE
7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Sernova's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sernova has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PSH News

Simply Wall St News

PSH Company Info

Description

Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch and associated technologies, including therapeutic cells and local immune protection. The company is developing a Cell Pouch system that is in Phase I/II clinical trial for the treatment of type-1 diabetes. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells for the treatment of chronic diseases, such as hemophilia A and thyroid diseases. Sernova Corp. is headquartered in London, Canada.

Details
Name: Sernova Corp.
PSH
Exchange: DB
Founded:
CA$26,340,461
172,237,348
Website: http://www.sernova.com
Address: Sernova Corp.
The Stiller Centre,
Suite 114,
London,
Ontario, N6G 4X8,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV SVA Common Shares TSX Venture Exchange CA CAD 29. Feb 2000
OTCPK SEOV.F Common Shares Pink Sheets LLC US USD 29. Feb 2000
DB PSH Common Shares Deutsche Boerse AG DE EUR 29. Feb 2000
Number of employees
Current staff
Staff numbers
0
Sernova employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 21:57
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/02/15
Last earnings filing: 2019/04/01
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.